The earnings call reflects a company navigating a transition period with both challenges and strategic wins. While revenue and profitability have declined due to the loss of the largest customer, Rockwell Medical has improved its cash position, secured long-term contracts, and maintained operational efficiency. The positive steps towards stabilizing the business suggest potential for future growth, but the recent financial performance remains a concern.
Company Guidance
During Rockwell Medical's Second Quarter 2025 conference call, the company reiterated its guidance for the year, projecting net sales between $65 million and $70 million, with a gross margin ranging from 16% to 18%. Adjusted EBITDA is expected to be between negative $500,000 and positive $500,000. The company highlighted its strategic focus on securing long-term contracts, with over 80% of its customers now under such agreements, which is a significant improvement from previous years. Despite a 38% decline in second-quarter net sales year-over-year, largely due to the transition of its largest customer to another supplier, Rockwell managed to improve its cash position to $18.4 million and maintain a consistent gross margin of 16%. The company also emphasized ongoing discussions with major customers and potential expansion opportunities in the Western United States, which could significantly impact future financials.
Improved Cash Position
Rockwell Medical improved its cash position to $18.4 million from $17.3 million at the end of Q1, driven by $1.8 million in cash flow from operations.
Long-Term Contracts Established
More than 80% of Rockwell's customers are now under long-term contracts, demonstrating stability and predictability in their business model.
New Product Purchase Agreements
Entered into a multimillion-dollar purchase agreement with Innovative Renal Care, and other significant agreements with large U.S. health systems.
Operational Efficiency Improvements
Investments in new equipment increased operational efficiency, stabilizing gross margins at 16% despite revenue decline.
Rockwell Med (RMTI) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RMTI Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 14, 2025
$1.04
$1.05
+0.96%
May 12, 2025
$1.12
$1.04
-7.14%
Mar 20, 2025
$1.76
$1.40
-20.45%
Nov 12, 2024
$4.65
$2.83
-39.14%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rockwell Medical Technologies (RMTI) report earnings?
Rockwell Medical Technologies (RMTI) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).
What is Rockwell Medical Technologies (RMTI) earnings time?
Rockwell Medical Technologies (RMTI) earnings time is at Nov 17, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.